STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
…
continue reading
Hosted by Colm Quinn, The CSIS Podcast dissects the big (and soon-to-be big) stories of the week in U.S. foreign policy and international affairs.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
35:18
35:18
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
35:18
We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year. We also chat about an upcoming presentation from Summit Therapeutics on its cancer drug that beat Merck’s Key…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
37:34
37:34
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
37:34
STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson's exit from his decades-long tenure at the University of Pennsylvania. We also discuss the latest news in the life sciences, including the surprising collapse of a gene editing company, Eli Lilly's pitch to consumers, and more.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
From "Say More": What Happens When AI Decides Your Medical Coverage
22:42
22:42
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
22:42
This week, STAT's Casey Ross and Bob Herman joined the Boston Globe's "Say More" podcast to talk about their reporting on AI and Healthcare. We're sharing that episode here with you now. Enjoy!STAT による
…
continue reading
![Artwork](/static/images/128pixel.png)
1
319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides
34:07
34:07
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
34:07
It's a guest-free episode this week, giving Allison, Adam and Elaine ample time to chat about the management shakeup at BioMarin, including the announcement that James Sabry, the former Roche dealmaker, was joining the company as its new chief business officer. We can't seem to go a week without talking about GLP-1 medicines, so in true form, Elain…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
318: Drug pricing drops & psychedelics under fire
21:16
21:16
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
21:16
STAT’s chief Washington correspondent Rachel Cohrs Zhang joins us to discuss the discounts and how this first round of negotiations between pharmaceutical companies and Medicare officials played out. After that, we chat with our colleague Meghana Keshavan about the latest news in the psychedelics world, including the retraction of three research pa…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
28:52
28:52
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
28:52
STAT's Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1. We also cover the latest news in the life sciences including the merger of AI drug development companies Recursion Pharmaceuticals and Exscientia, Novo Nordisk's decisi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates
34:15
34:15
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
34:15
Andrew Joseph, STAT's Europe correspondent, joins us to talk about his special report on the 40-year quest to develop the world's first malaria vaccines. We also cover the latest news in the biotech industry, including Sarepta Therapeutics' move to censor a patient video, data from a new Duchenne gene therapy, and a campaign by Mount Sinai to stifl…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves
32:46
32:46
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
32:46
What makes UnitedHealth similar to Standard Oil? Is Viking Therapeutics an attractive acquisition target? And is Adam good at math? We discuss all that and more in this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Tara Bannow, our hospitals and insurance reporter, joins us to talk about a new investigation that shows how UnitedHeal…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
33:02
33:02
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
33:02
Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, short…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
313: Biotech layoffs, founder-focused VC, & a big pharma exit
34:52
34:52
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
34:52
STAT's West Coast biotech reporter Jonathan Wosen joins "The Readout LOUD" to discuss what’s driving workforce cuts. Plus, entrepreneurs Alexis Borisy and Zach Weinberg call in to discuss their biotech incubator Curie.Bio and how they hope to “free the founders.” We also discuss a big change in Pfizer’s leadership and the debate over a new side eff…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
28:33
28:33
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
28:33
STAT health tech reporter Brittany Trang guest co-hosts "The Readout LOUD" this week, where we discuss AI for drug development, the latest in the H5N1 bird flu outbreak, a surprise entrant to the GLP-1 field, and more news in the life sciences. And STAT chief Washington correspondent Rachel Cohrs Zhang joins the podcast to talk about a new proposal…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review
34:10
34:10
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
34:10
STAT reporter Jason Mast joins us to discuss Anthony Fauci's memoir "On Call," which was published this week. Hosts Allison DeAngelis and Adam Feuerstein also dissect Alnylam's forthcoming clinical trial data and take stock of how the biotech markets are succeeding and potentially falling flat midway through the year. For more on Fauci's memoir "On…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)
38:46
38:46
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
38:46
STAT's Nicholas Florko joins to explain what it means to be a reporter writing about the commercial determinants of health. Hint: Florko's most recent stories focus on weed, vapes, and raw milk. And instead of being chained to a desk, he often drives around to convenience stores and buy bad stuff — all in the name of good journalism. But first, co-…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
29:34
29:34
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
29:34
STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics' meeting with an FDA advisory committee. We also discuss the latest news in the health and life sciences, including stories from major biotech conferences. To learn more about Lykos' advisory committee meeting, go here; for more on the tumult at BIO, go here; for a recap of ASCO…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
308: An ASCO preview & another Duchenne trial failure
28:34
28:34
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
28:34
We preview some of the research that will be presented at The American Society of Clinical Oncology conference in Chicago. We also discuss the latest news in the health and life sciences, including a milestone in lung disease R&D and a Duchenne muscular dystrophy confirmatory trial failure. To read more about Merus' combination therapy, go here; Fo…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
307: More tumult at BIO & coercive care for sickle cell patients
31:07
31:07
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
31:07
This week on “The Readout LOUD,” STAT's Chief Washington Correspondent Rachel Cohrs Zhang joins us to discuss the layoffs at trade group BIO and how things may be changing at the trade group. We also invite STAT reporter Eric Boodman on to talk about his new investigative series of stories exploring how Black women with sickle cell disease were coe…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
306: Live! From the STAT Breakthrough Summit West
23:08
23:08
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
23:08
On this week’s "Readout LOUD," we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that note, we chat with our AI correspondent — and recent Pulitzer finalist — Casey Ross, who sat down on stage to discuss AI-centered drug discovery with both NVIDIA and Google-backed Isomorphic Labs. We als…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
305: Everything you need to know about H5N1 bird flu
31:52
31:52
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
31:52
This week on "The Readout LOUD," STAT senior infectious diseases reporter Helen Branswell walks us through ongoing H5N1 outbreak in the U.S. and issues with monitoring the spread. And in a bit of shameless self-promotion, we’ll talk to our colleagues Bob Herman and Casey Ross about being named Pulitzer finalists in investigative reporting for their…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama
33:04
33:04
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
33:04
The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Reado…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
31:45
31:45
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
31:45
We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teledoc CEO Jason Gorevic parted ways with the company after spending 15 years building the telemedicine field. Here's where you can subscribe to our biotech newsletter, The Readout…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
302: Vertex's big deal, biotech's red numbers, & an industry history lesson
24:48
24:48
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
24:48
How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss a multibillion-dollar deal from Vertex Pharmaceuticals with sweeping implications and a lengthy backstory. We also explain why gas prices are weighing on biotech, and make a…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
31:37
31:37
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
31:37
Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans. Here’s w…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
34:21
34:21
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
34:21
Our colleague Sarah Owermohle joins us to explain the Supreme Court case that could have dramatic effects on access to medication abortion — and the development of new medicines. We also discuss the latest news in the life sciences, including a contrarian take on a new obesity treatment, a congressional effort to ban Chinese biotech companies, and …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
299: Live! From the STAT Breakthrough Summit East
33:54
33:54
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
33:54
Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientist George Yancopoulos. We also discuss the latest news in the life sciences, including a twist in the GLP-1 story, the cost of gene therapy, and, of co…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
35:21
35:21
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
35:21
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver…
…
continue reading